Valeant Pharmaceuticals International (NYSE:VRX) stated gains of 6,344,671 shares or 24.2% in the short interest. The short interest registered from 26,259,693 on May 31,2016 to 32,604,364 on June 15,2016. In terms of floated shares, the shorted positions stood at 9.8%. The stock has been averaging 34,687,448 shares daily in trading and would need 1 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $21.16 on Friday but the bulls could not build on the opening and the stock topped out at $21.48 for the day. The stock traded down to $20.21 during the day, due to lack of any buying support eventually closed down at $20.27 with a loss of -8.90% for the day. The stock had closed at $22.25 on the previous day. The total traded volume was 27,977,033 shares.
The company shares have dropped -90.80% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $263.81 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $25.81 and the 200 Day Moving Average price is recorded at $58.14.
Valeant Pharmaceuticals International (NYSE:VRX) has tumbled 8.03% during the past week and has dropped 28.68% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 6.5%. Valeant Pharmaceuticals International (NYSE:VRX) has underperformed the index by 26.52% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.